MaxCyte
Cell & Gene Therapy · Bioprocessing

MaxCyte revenue, results and funding

MaxCyte filed revenue of $33M for 2025.

Data updated Nov 20, 2026 · Back to the company report
$33MRevenue, 2025
−$44.6MNet income, 2025
$760kTotal raised

Results by year

YearRevenueNet incomeTotal assetsLANG_CR_S_M_TAX_EXPENSELANG_CR_S_M_CAPEXLANG_CR_S_M_SBCLANG_CR_S_M_RNDLANG_CR_S_M_OPERATING_INCOMELANG_CR_S_M_CASHLANG_CR_S_M_ACQUISITIONS
2025$33M−$44.6M$202.5M–$1.8M$9.2M$20.8M−$51.9M$20.1M$1.8M
2024$38.6M−$41.1M$239.5M–$1.7M$13.1M$22.2M−$51.2M$27.9M–
2023$41.3M−$37.9M$268.3M–$3.7M$14M$23.8M−$48.3M$46.5M–
2022$44.3M−$23.6M$286.7M–$18.5M$11.8M$19.5M−$27.4M$11.1M–
2021$33.9M−$19.1M$284.1M$0$3.8M$8M$15.4M−$18.2M$47.8M–
2020$26.2M−$11.8M$51.8M$0$2.1M$2.5M$17.7M−$11.1M$18.8M–
2019$21.6M−$12.9M–$0$1.3M$1.8M$17.6M−$12.4M––
Sources: SEC

Rounds and grants

YearRoundAmount
2016Venture$760k
Sources: funding announcements, SEC filings, grant registers

How to cite

MaxCyte, Financials. Alion, Nov 20, 2026. https://alion.io/company/maxcyte/financials

.json · .md · CC BY-SA 4.0